Genflow Biosciences Plc operates as a biotechnology company, which engages in the research and development of gene therapies to counteract the effects of aging and diseases associated with advanced age. The firm is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The firm's product pipeline includes GF-1002, GF-1003, GF-1004, GF-1005 and GF-1006. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-1004 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-1003 is a formulation of an adeno-associated viral vector-based gene therapy. The firm has operations in the United Kingdom and Belgium.
Follow-Up Questions
Qui est le CEO de Genflow Biosciences PLC ?
Dr. Eric Leire est le Chief Executive Officer de Genflow Biosciences PLC, il a rejoint l'entreprise depuis 2021.
Quelle est la performance du prix de l'action GENFF ?
Le prix actuel de GENFF est de $0.0193, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Genflow Biosciences PLC ?
Genflow Biosciences PLC appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Genflow Biosciences PLC ?
La capitalisation boursière actuelle de Genflow Biosciences PLC est de $8.7M
